A woman who had suffered for more than a decade from three serious and life-threatening autoimmune diseases was able to return to a near-normal life after undergoing cell therapy that reset her rebellious immune system.
Prior to this treatment, the 47-year-old woman had tried nine different types of therapies, but none of them had a long-lasting effect.
Her condition was so deteriorated that she needed daily blood transfusions and permanent blood-thinning medication to control her illnesses.
Last year, she received treatment at the University of Erlangen in Germany, a treatment known as CAR-T cell therapy , which has proven highly effective in treating certain types of cancer. Just weeks later, doctors observed a remarkable improvement in all three diseases, a world first of its kind.
What was unique about this case was that the woman suffered from three autoimmune diseases simultaneously: first, autoimmune hemolytic anemia (AIHA), in which the immune system destroys red blood cells; second, immune thrombocytopenic purpura (ITP), in which immune cells destroy platelets, increasing the risk of bleeding; and third, antiphospholipid syndrome (APS), which increases the risk of blood clots. All three diseases were caused by a defect in a type of immune cell called a B cell.
The doctors extracted the woman's white blood cells, then isolated immune cells called "T cells" from them. They genetically engineered these T cells to recognize a protein on the surface of the rogue "B cells," then reinjected them into her body. These modified cells destroyed the diseased "B cells," thus halting the immune system's attacks.
Just one week after starting treatment, the woman no longer needed blood transfusions. Two weeks later, she was strong enough to resume her daily activities. Now, 14 months later, she remains completely remission, requiring no further treatment, with her B cells fully recovered and healthy.
The woman still has a slight decrease in white blood cell count and a slight increase in liver enzymes, but researchers believe this is due to years of previous treatments and not to the CAR-T treatment itself.
Professor Fabian Müller, the lead physician, described the woman's response as "remarkable," emphasizing that the treatment "significantly improved her quality of life." However, he stressed the need for further clinical trials to determine the treatment's long-term effectiveness and its potential success with other patients.
Professor Ben Parker, a consultant rheumatologist in Manchester, said that the woman's continued improvement over a long period without treatment suggests a genuine "immune reset," but added that individual case reports do not prove the treatment's effectiveness for widespread use, which is why we need clinical trials involving larger numbers of patients.
